肉腫治療薬の市場規模、シェア、動向分析レポート：治療タイプ別、流通チャネル別、地域別、セグメント予測、2023年～2030年

肉腫治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の肉腫治療薬市場規模は2030年までに25億3,450万米ドルとなり、2023年から2030年までのCAGRは8.9%で推移すると予測されています。

市場の成長は、新製品の上市、新規治療薬の採用増加、対象人口の増加などの要因によって大きく左右されます。

肉腫は成人がん全体の1.0％未満です。肉腫は50以上の異なる組織型からなる不均一なグループであるが、2つの主要なサブタイプは軟部肉腫（STS）と骨肉腫です。米国では毎年約12,000人、欧州では毎年約28,000人の患者がSTSと診断されています。

40年以上にわたり、限局性肉腫の治療の主流は外科的切除に続くネオアジュバントまたはアジュバント放射線療法や化学療法でした。しかし、外科的切除を完全に行っても、中悪性度または高悪性度の肉腫患者の約50.0％が転移を起こします。標的治療のイントロダクションは肉腫の治療パラダイムに革命をもたらしました。標的療法とパイプラインのブレークスルーは、予測期間を通じて市場の成長に極めて重要な役割を果たし続けるであろう。

肉腫治療薬市場レポートハイライト

• EU5は2022年までに20%以上のシェアを獲得し、第2位の市場として存続します。このセグメントの成長は、STSの罹患率の上昇、標的治療の普及、研究開発活動の活発化に起因しています。
• Eli Lilly社のLartuvoは、標準的なドキソルビシン療法に代わってSTSのフロントライン治療薬となっており、予測期間中も市場での優位性を維持すると予想されます。
• 同市場ではアンメットニーズが強く、画期的なファースト・イン・クラスの治療薬を開発する重要な機会となっています。肉腫のパイプラインにある45の薬剤のうち、7つがフェーズIII、22がフェーズII、2つがフェーズI/II試験中で、残りはフェーズIと前臨床試験中です。
• 肉腫における免疫腫瘍薬の役割の可能性は、現在第I/II相臨床試験で評価中です。
• 初期段階の開発段階にある新規ターゲットの薬剤には、ノバルティスのAfinitor（mTOR阻害剤）、テサロのZejula（PARP阻害剤）、アムジェンのImlygic（遺伝子治療）、ファイザーのCrizotinib（ALKおよびMETチロシンキナーゼ阻害剤）などがあります。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 肉腫治療薬市場：変数、動向、範囲

• 市場系統の見通し
• 普及と成長の見通しマッピング
• 業界のバリューチェーン分析
• 市場力学
• 肉腫治療薬市場分析ツール

第4章 肉腫治療薬市場：治療タイプの推定・動向分析

• 肉腫治療薬市場：重要なポイント
• 肉腫治療薬市場：動向と市場シェア分析、2022年および2030年
• 化学療法
• 標的療法

第5章 肉腫治療薬市場：流通チャネルの推定・動向分析

• 肉腫治療薬市場：重要なポイント
• 肉腫治療薬市場：動向と市場シェア分析、2022年および2030年
• 病院薬局
• 小売薬局
• オンライン薬局

第6章 肉腫治療薬市場：地域推定・動向分析

• 地域別の見通し
• 肉腫治療薬市場：地域別：主要マーケットプレースの要点
• 北米
  • 市場推計・予測、2018～2030年
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • スウェーデン
  • ノルウェー
  • デンマーク
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • タイ
  • 韓国
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • サウジアラビア
  • 南アフリカ
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 市場参入企業の分類
  • Pfizer Inc.
  • Novartis International AG
  • Eli Lilly and Company
  • Bayer AG
  • Eisai Co.
  • Johnson & Johnson
  • Merck & Co. Inc
  • Daiichi Sankyo Company, Limited

List of Tables

• Table 1 List of Abbreviations
• Table 2 North America sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 3 North America sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 4 North America sarcoma drugs market: by region, 2018 - 2030 (USD Million)
• Table 5 U.S. sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 6 U.S. sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 7 Canada sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 8 Canada sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 9 Europe sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 10 Europe sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 11 Europe sarcoma drugs market: by region, 2018 - 2030 (USD Million)
• Table 12 Germany sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 13 Germany sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 14 UK sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 15 UK sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 16 France sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 17 France sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 18 Italy sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 19 Italy sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 20 Spain sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 21 Spain sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 22 Sweden sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 23 Sweden sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 24 Norway sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 25 Norway sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 26 Denmark sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 27 Denmark sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 28 Asia Pacific sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 29 Asia Pacific sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 30 Asia Pacific sarcoma drugs market: by region, 2018 - 2030 (USD Million)
• Table 31 China sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 32 China sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 33 China sarcoma drugs market: by application, 2018 - 2030 (USD Million)
• Table 34 Japan sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 35 Japan sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 36 Japan sarcoma drugs market: by application, 2018 - 2030 (USD Million)
• Table 37 India sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 38 India sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 39 Australia sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 40 Australia sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 41 Thailand sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 42 Thailand sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 43 South Korea sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 44 South Korea sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 45 Latin America sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 46 Latin America sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 47 Latin America sarcoma drugs market: by region, 2018 - 2030 (USD Million)
• Table 48 Brazil sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 49 Brazil sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 50 Mexico sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 51 Mexico sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 52 Argentina sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 53 Argentina sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 54 Middle East and Africa sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 55 Middle East and Africa sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 56 Middle East and Africa sarcoma drugs market: by region, 2018 - 2030 (USD Million)
• Table 57 South Africa sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 58 South Africa sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 59 Saudi Arabia sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 60 Saudi Arabia sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 61 UAE sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 62 UAE sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
• Table 63 Kuwait sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
• Table 64 Kuwait sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Sarcoma drugs market: Market outlook
• Fig. 9 Sarcoma drugs market: Competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 Sarcoma drugs market: driver impact
• Fig. 15 Sarcoma drugs market: restraint impact
• Fig. 16 Sarcoma drugs market: Strategic Initiatives analysis
• Fig. 17 Sarcoma drugs market: Treatment type movement analysis
• Fig. 18 Sarcoma drugs market: Treatment type outlook and key takeaways
• Fig. 19 Chemotherapy market estimates and forecasts, 2018 - 2030
• Fig. 20 Targeted therapy & others market estimates and forecasts, 2018 - 2030
• Fig. 21 Sarcoma drugs market: Distribution channel movement analysis
• Fig. 22 Sarcoma drugs market: Distribution channel outlook and key takeaways
• Fig. 23 Hospital pharmacy market estimates and forecasts, 2018 - 2030
• Fig. 24 Retail pharmacy market estimates and forecasts, 2018 - 2030
• Fig. 25 Online pharmacy market estimates and forecasts, 2018 - 2030
• Fig. 26 Global Sarcoma drugs market: Regional movement analysis
• Fig. 27 Global Sarcoma drugs market: Regional outlook and key takeaways
• Fig. 28 North America market estimates and forecasts, 2018 - 2030
• Fig. 29 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 30 Canada market estimates and forecasts, 2018 - 2030
• Fig. 31 Europe market estimates and forecasts, 2018 - 2030
• Fig. 32 UK market estimates and forecasts, 2018 - 2030
• Fig. 33 Germany market estimates and forecasts, 2018 - 2030
• Fig. 34 France market estimates and forecasts, 2018 - 2030
• Fig. 35 Italy market estimates and forecasts, 2018 - 2030
• Fig. 36 Spain market estimates and forecasts, 2018 - 2030
• Fig. 37 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 38 Norway market estimates and forecasts, 2018 - 2030
• Fig. 39 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 40 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 41 Japan market estimates and forecasts, 2018 - 2030
• Fig. 42 China market estimates and forecasts, 2018 - 2030
• Fig. 43 India market estimates and forecasts, 2018 - 2030
• Fig. 44 Australia market estimates and forecasts, 2018 - 2030
• Fig. 45 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 46 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 47 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 48 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 49 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 50 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 51 Middle East and Africa. market estimates and forecasts, 2018 - 2030
• Fig. 52 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 53 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 54 UAE market estimates and forecasts, 2018 - 2030
• Fig. 55 Kuwait market estimates and forecasts, 2018 - 2030

Sarcoma Drugs Market Growth & Trends:

The global sarcoma drugs market size is expected to be valued at USD 2534.5 million by 2030, as per a new report by Grand View Research, Inc.., progressing at a CAGR of 8.9% from 2023 to 2030. The growth of the market is largely driven by factors such as new product launches, increasing adoption of novel therapeutics, and growing target population.

Sarcomas account for less than 1.0% of all adult cancers. Though sarcomas represent a heterogeneous group of over 50 different histological subtypes, the two major subtypes are soft tissue sarcomas (STS) and bone sarcoma. Approximately, 12,000 patients in the U.S. and 28,000 patients in Europe are diagnosed with STS every year.

For over 40 years, the mainstay of localized sarcoma treatment included surgical resection followed by neoadjuvant or adjuvant radiation or chemotherapy. However, even after complete surgical resection, about 50.0% of patients with intermediate or high grade sarcoma develop metastatic disease. The introduction of targeted therapy has revolutionized the treatment paradigm for sarcoma. Targeted therapies and pipeline breakthroughs will continue to play a pivotal role in the growth of the market throughout the forecast period.

Sarcoma Drugs Market Report Highlights:

• EU5 will remain the second largest market with more than 20% share by 2022. The growth of the segment can be attributed to the rising incidence of STS, uptake of targeted therapies, and increasing R&D activities
• Eli Lilly's Lartuvo has displaced standard doxorubicin therapy as front-line STS treatment and is anticipated to maintain its prominence in the market over the forecast period
• Strong unmet needs within the market present a key opportunity to develop breakthrough first-in-class therapies. Out of 45 drugs in the pipeline for sarcoma, seven are in Phase III, 22 in Phase II, two in Phase I/II trials, and the remaining in Phase I and Pre-clinical trials
• The potential role for use of immuno-oncology agents in sarcomas is currently under evaluation in Phase I/II clinical trials
• Drugs with novel targets in early-phase development include Novartis's Afinitor (mTOR inhibitor), Tesaro's Zejula (PARP inhibitor), Amgen's Imlygic (gene therapy), and Pfizer's Crizotinib (ALK and MET tyrosine kinases inhibitor)

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Treatment type
  • 1.1.2. Distribution channel
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment type outlook
  • 2.2.2. Distribution channel outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Sarcoma Drugs Market: Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Industry Value Chain Analysis
  • 3.3.1. Reimbursement framework
• 3.4. Market Dynamics
• 3.5. Sarcoma Drugs Market Analysis Tools
  • 3.5.1. Industry Analysis - Porter's
    • 3.5.1.1. Supplier power
    • 3.5.1.2. Buyer power
    • 3.5.1.3. Substitution threat
    • 3.5.1.4. Threat of new entrant
    • 3.5.1.5. Competitive rivalry
  • 3.5.2. PESTEL Analysis
    • 3.5.2.1. Political landscape
    • 3.5.2.2. Technological landscape
    • 3.5.2.3. Economic Landscape

Chapter 4. Sarcoma Drugs Market: Treatment Type Estimates & Trend Analysis

• 4.1. Sarcoma Drugs Market: Key Takeaways
• 4.2. Sarcoma Drugs Market: Movement & Market Share Analysis, 2022 & 2030
• 4.3. Chemotherapy
  • 4.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.4. Targeted therapy
  • 4.4.1. Targeted therapy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Sarcoma Drugs Market: Distribution Channel Estimates & Trend Analysis

• 5.1. Sarcoma Drugs Market: Key Takeaways
• 5.2. Sarcoma Drugs Market: Movement & Market Share Analysis, 2022 & 2030
• 5.3. Hospital pharmacy
  • 5.3.1. Hospital pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.4. Retail pharmacy
  • 5.4.1. Retail pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Online pharmacy
  • 5.5.1. Online pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Sarcoma Drugs Market: Regional Estimates & Trend Analysis

• 6.1. Regional Outlook
• 6.2. Sarcoma Drugs Market: by Region: Key Marketplace Takeaway
• 6.3. North America
  • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.3. France
    • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.6. Sweden
    • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.7. Norway
    • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.2. China
    • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.3. India
    • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.5. Thailand
    • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.6. South Korea
    • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.2. Mexico
    • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.7. MEA
  • 6.7.1. Saudi Arabia
    • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.2. South Africa
    • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Market Participant Categorization
  • 7.2.1. Pfizer Inc.
    • 7.2.1.1. Company overview
    • 7.2.1.2. Financial performance
    • 7.2.1.3. Product benchmarking
    • 7.2.1.4. Strategic initiatives
  • 7.2.2. Novartis International AG
    • 7.2.2.1. Company overview
    • 7.2.2.2. Financial performance
    • 7.2.2.3. Product benchmarking
    • 7.2.2.4. Strategic initiatives
  • 7.2.3. Eli Lilly and Company
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Bayer AG
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Eisai Co.
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Johnson & Johnson
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Merck & Co. Inc
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. Daiichi Sankyo Company, Limited
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives